Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Farmers Insurance
Covington
UBS
McKesson
QuintilesIMS
Accenture
Novartis
Fish and Richardson
US Department of Justice

Generated: August 22, 2017

DrugPatentWatch Database Preview

Daiichi Company Profile

« Back to Dashboard

What is the competitive landscape for DAIICHI, and what generic alternatives to DAIICHI drugs are available?

DAIICHI has eleven approved drugs.

There are five US patents protecting DAIICHI drugs.

There are two hundred and fifty-nine patent family members on DAIICHI drugs in thirty-six countries.

Summary for Applicant: Daiichi

Patents:5
Tradenames:9
Ingredients:9
NDAs:11
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo
AZOR
amlodipine besylate; olmesartan medoxomil
TABLET;ORAL022100-001Sep 26, 2007ABRXYesNo► Subscribe► Subscribe ► Subscribe
Daiichi Sankyo
TRIBENZOR
amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL200175-004Jul 23, 2010ABRXYesNo► Subscribe► Subscribe ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-002Jan 8, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
CAPSULE;ORAL021141-001May 26, 2000DISCNNoNo► Subscribe► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
FOR SUSPENSION;ORAL022362-001Oct 2, 2009RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Daiichi

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
FOR SUSPENSION;ORAL022362-002Oct 2, 2009► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
CAPSULE;ORAL021141-001May 26, 2000► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
CAPSULE;ORAL021141-001May 26, 2000► Subscribe► Subscribe
Daiichi Sankyo
BENICAR HCT
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL021532-005Jun 5, 2003► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
CAPSULE;ORAL021141-001May 26, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for DAIICHI drugs

Drugname Dosage Strength Tradename Submissiondate
colesevelam hydrochloride
Powder for Oral Suspension1.875 g/Packet and 3.75 g/Packet
WELCHOL
4/9/2010
colesevelam hydrochloride
Tablets625 mg
WELCHOL
7/1/2009
cevimeline hydrochloride
Capsules30 mg
EVOXAC
2/27/2009
amlodipine besylate and olmesartan medoxomil
Tablets10 mg/20 mg and 5 mg/40 mg
AZOR
3/31/2008
amlodipine besylate and olmesartan medoxomil
Tablets5 mg/20 mg and 10 mg/40 mg
AZOR
2/11/2008
olmesartan medoxomil and hydrochlorothiazide
Tablets20 mg/12.5 mg
BENICAR HCT
5/11/2007
olmesartan medoxomil and hydrochlorothiazide
Tablets40 mg/12.5 mg and 40 mg/25 mL
BENICAR HCT
2/15/2007
olmesartan medoxomil
Tablets5 mg, 20 mg and 40 mg
BENICAR
4/25/2006

Non-Orange Book Patents for Daiichi

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,646,171 Angiotensin II antagonist 1-biphenylmethylimidazole compounds and their therapeutic use► Subscribe
7,342,014Diamine derivatives► Subscribe
7,541,024Low salt forms of polyallylamine► Subscribe
7,261,880Methods of treating Syndrome X with aliphatic polyamines► Subscribe
8,377,428Low salt forms of polyallylamine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Daiichi Drugs

Country Document Number Estimated Expiration
MexicoPA03009571► Subscribe
Israel101034► Subscribe
South Korea20040018359► Subscribe
Australia2008286914► Subscribe
Finland955248► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Daiichi Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
80016Netherlands► SubscribePRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606
C/GB03/024United Kingdom► SubscribePRODUCT NAME: OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHAMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE 50202.00.00 20020813; DE 50202.01.00 20020813; DE 50202.02.00 20020813; DE 50205.00.00 20020813; DE 50205.01.00 20020813; DE 50205.02.00 20020813; UK PL 08265/0015 20030522; UK PL 08265/0016 20030522; UK PL08265/0017 20030522
00486Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216
00478Netherlands► SubscribePRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN AMLODIPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER AMLODIPINEBESILAAT; REGISTRATION NO/DATE: EU/1/10/648/001-028 20101007
00095Netherlands► SubscribePRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
US Army
Express Scripts
Accenture
Johnson and Johnson
Colorcon
Fish and Richardson
Medtronic
Healthtrust
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot